All procedures involved in this study were approved by the University of Florida (UF) Institutional Review Board following the Declaration of Helsinki. The IRB number is 202100659, with an approval date of July 26, 2022.
Study Participants
Forty-three autistic adults and forty-three neurotypical controls participated in this study. Participants were between 30 and 73 years old and groups were matched on age, sex, and intelligence quotient (IQ) (Table 1). Autistic adults were identified and recruited from the Center for Autism and Related Disabilities (CARD) at the University of Florida in Gainesville, the University of Central Florida, the University of South Florida, and the SPARK Research Match. Neurotypical controls were recruited primarily from communities in north central Florida through study flyers and word of mouth. All participants provided written informed consent after receiving a complete description of the study. All participants completed the Repetitive Behavior Scale-Revised (RBS-R) [32] and had their IQ assessed using the Wechsler Abbreviated Scales of Intelligence, 2nd Edition (WASI-II) [33].
Table 1
Demographic and clinical characteristics between autistic adults (ASD) and neurotypical controls (NT)
| ASD Mean (± SD) | NT Mean (± SD) | t/χ2 | p | |
Age (years) Range | 47.21 (± 10.86) 30–73 | 49.79 (± 12.01) 30–70 | -1.05 | 0.299 | |
Sex (M/F) b | 25/18 | 23/20 | 0.19 | 0.664 a | |
Handedness (R/L/B) a/b | 39/3/1 | 39/4/0 | 1.14 | 0.565 a | |
Full-scale IQ | 107.44 (± 13.71) | 107.87 (± 11.02) | -0.16 | 0.877 | |
Verbal IQ | 107.72 (± 13.78) | 106.21 (± 11.23) | 0.54 | 0.589 | |
Non-verbal IQ | 105.33 (± 13.90) | 107.90 (± 13.49) | -0.85 | 0.399 | |
AQ | 34.72 (± 7.25) | 13.84 (± 5.64) | 14.07 | < .001*** | |
SRS-2 | 76.47 (± 7.91) | 45.23 (± 3.96) | 9.93 | < .001*** | |
ADOS-2 | 10.72 (± 3.31) | n/a | | | |
RBS-R | 44.44 (± 26.88) | 3.28 (± 3.73) | 21.21 | < .001*** | |
Total brain volume (cm3) | 1555.34 (± 161.11) | 1515.17 (± 146.34) | 1.21 | 0.230 |
a Self-reported handedness: R = right-hand dominant, L = left-hand dominant, and B = ambidextrous |
b Chi-square (χ2) statistics |
Total raw scores were reported for ADOS-2, AQ, and RBS-R; t scores were applied for SRS-2 |
Statistical significance is in bold-faced. *p < 0.05, **p < 0.01, ***p < 0.001 |
Supplementary materials |
[Insert Supplementary Fig. 1 about here] |
Supplementary Fig. 1. b dispersion plots for 32 transcallosal tracts (top panel) and 94 gray matter ROIs (bottom panel) of autistic adults (rose red) and neurotypical controls (sky blue). Dispersion plots for FA (A), free water (B), and fwcFA (C) are arranged from the left to the right. The that sits in the middle of each dispersion plot represents the [Mean ± SE] of b value for each autism or control group. The [Mean]s of b values derived from each of the frontal, temporal, parietal, and occipital cortices are displayed at the bottom panel of each dispersion plot cluster and labeled by. The lines connecting these red and blue dots represent the b mean difference between the autism and control groups. |
[Insert Table 1 about here]
Prospective autistic adults with a clinical diagnosis of ASD were screened using the Autism Spectrum Quotient for Adults (AQ) [34] and the Social Responsiveness Scale Adult Self-Report (SRS-2) [35]. The AQ comprises five sub-scales that evaluate individuals’ social skill, attention switching, attention to detail, communication skill, and imagination. The SRS-2 includes sub-scale assessments on social awareness, social cognition, social communication, social motivation, restricted interest, and repetitive behavior. Individuals who scored \(\:>\) 32 on the AQ and \(\:\ge\:\) 65 on the SRS-2 were invited to receive a diagnostic evaluation using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) [36] at the UF CARD. Diagnosis for autistic adults was confirmed through a comprehensive review of AQ, SRS-2, ADOS-2, and expert clinical opinion following the DSM-5 criteria [37]. Three autistic adults did not meet the cut-off for AQ or SRS-2 but scored > 7 on ADOS-2. Their diagnosis was later confirmed by research reliable clinicians (AMO and RAR) on our team. Autistic adults were excluded if they had a known genetic or metabolic disorder associated with ASD (e.g., Fragile X syndrome, Rett syndrome, Phelan McDermid syndrome, tuberous sclerosis).
Prospective controls who scored \(\:\le\:\) 22 on the AQ and < 60 on the SRS-2 were recruited to the study. Prospective controls were excluded if they reported a family history of ASD or other neurodevelopmental disorders in their first- and second-degree relatives. Prospective autistic adults and controls who met any of the following criteria were excluded from the present study: 1) confirmed diagnosis of intellectual disability, mild cognitive impairment, or dementia; 2) confirmed diagnosis of non-specific developmental delay; 3) recent history of or current major psychiatric conditions (e.g., schizophrenia, bipolar disorder or post-traumatic stress disorder); 4) recent history of or current medical illness that significantly affects the structure and/or function of the central nervous system (e.g., brain tumor, thyroid disease, Cushing’s disease, or HIV infection); 5) confirmed diagnosis of a neurological disorder (e.g., stroke, dystonia, seizure disorders, Parkinson’s disease, or cerebellar ataxia); 6) family history of a hereditary neurological disorder (e.g., Huntington’s Chorea, Wilson’s Disease, or amyotrophic lateral sclerosis); 7) substance use disorder within six months prior to testing or a significant long-term history of substance use disorder; 8) wearing implanted medical devices (e.g., pumps, cardiac pacemakers, or cochlear implants); 9) pregnant; 10) had a full-scale IQ (fs-IQ) < 75, or 11) non-English speaking.
Lastly, one autistic adult reported birth asphyxia, and two autistic adults reported prolonged delivery at birth. Nine autistic adults reported a history of concussion due to risky play during childhood or car collisions during adulthood. Medication being used within 48 hours prior to testing included antipsychotics (ASD = 4), mood stabilizers (ASD = 2), stimulants (ASD = 7), antidepressants (ASD = 26, NT = 4), and sedatives (ASD = 6, NT = 2).
dMRI data acquisition
The MRI session was administered on a 3T Siemens Prisma scanner with a 64-channel head coil at the UF McKnight Brain Institute. dMRI images were acquired using an echo-planar imaging sequence with the following parameters: TR = 6400 ms, TE = 58 ms, voxel size = 2.0 mm x 2.0 mm x 2.0 mm, b-values: 5 × 0, and 64 × 1,000 s/mm2, field of view = 256 x 256, number of continuous slices = 69, and bandwidth = 2442 Hx/pixel. Participants wore earplugs and headphones to minimize discomfort from instrumental noise. Head motion was restricted using foam paddings inserted around the head. The scan took about 7 minutes and 41 seconds to complete.
dMRI data post-processing and analysis
All dMRI data underwent post-processing and analysis using FMRIB Software Library 6.0 (FSL, fsl.fmrib.ox.ac.uk; [38, 39]). dMRI data were corrected for eddy current induced distortions and head motion using a three-dimensional (3D) affine transformation for all participants. Gradient directions were then rotated to reflect these corrections, and brain data were extracted afterward [40, 41]. A diffusion tensor model was fit to the eddy and motion corrected data to determine voxel-wise FA. Consistent with prior work from our group and others [15, 17, 42], we calculated a whole brain free water map for each individual to estimate the fractional volume of freely diffusing water in each voxel using custom MATLAB scripts (R2023a, The Mathworks, Natick, MA, USA). The free water map was then applied to correct the FA map, leading to a free water corrected FA (fwcFA) map. All images were registered to in-house templates via a nonlinear warping procedure using the SyNCC option in the Advanced Normalization Tools (ANTs) [43]. The registration procedure applied both an affine and deformation transformation to the whole brain maps using cross correlation as the optimization metric. Whole brain FA, free water, and fwcFA maps were transformed to Montreal Neurological Institute (MNI) 152 standard space (1 mm isotropic). After artifact inspection, mean diffusion metrics were derived from these maps for white and gray matter.
We extracted the mean of FA, free water, and fwcFA from white matter using the transcallosal tractography template (TCATT; [42]) and gray matter using the Mayo Clinic Adult Lifespan Template (MCALT; [44]). The TCATT is an ROI-based template that consists of 32 commissural tracts between homotopic regions of both hemispheres in 3D. This template includes transcallosal tracts from the frontal (17), temporal (3), parietal (6), and occipital (6) cortices [42]. Using an innovative slice-level thresholding approach, TCATT advances the spatial resolution of transcallosal tracts and reduces the likelihood of false positives relative to conventional templates [42]. The MCALT was constructed from T1-weighted scans of 202 healthy controls aged > 30 years [44] making it suitable for our study given the wide age range. The MCALT includes 94 ROIs from the frontal (36), temporal (22), parietal (16), occipital (12) cortices and subcortical (8) regions. The mean values of FA, free water and fwcFA were derived for each transcallosal tract and gray matter ROI, totaling 378 [(32 transcallosal tracts + 94 ROIs) \(\:\times\:\) 3 diffusion measures = 378] dependent variables.
Statistical Analyses
Demographic and clinical characteristics. Demographic and clinical characteristics between autistic adults and neurotypical controls were compared using independent t-tests for continuous variables and Chi-square tests for categorical variables. Statistical significance was set to p < 0.05.
Between group comparisons. Prior to inferential statistical analysis, a Shapiro-Wilk test was applied to assess the normality of all dependent variables. A total of 76.7% of the diffusion measures failed the test. We, therefore, implemented a one-way analysis of covariance (ANCOVA) with 5,000 permutations to assess between-group differences on each diffusion measure (i.e., FA, free water, or fwcFA) [45]. Each ANCOVA model consisted of group (ASD vs. NT) as the independent variable, a diffusion measure as the dependent variable, and age and sex as covariates. We introduced age and sex to ANCOVAs because our data comprised a wide age range, and sex has been shown to demonstrate a substantial impact on imaging measures in both autistic adults and neurotypical controls [46–48].
Age effect. Nonparametric partial correlation analyses with 5000 permutations were applied to examine the age effect on each diffusion metric separately for autistic adults and neurotypical controls [49]. Each correlation model consisted of age (\(\:{X}_{age}\)) as the independent variable, a diffusion measure (\(\:Y\)) as the dependent variable, and sex (\(\:{Z}_{sex}\)) as the covariate following the formula below [50–52]:
\(\:Y\:=\:\alpha\:+{X}_{age}\cdot\:\beta\:+{Z}_{sex}\cdot\:\gamma\:+\epsilon\:\) (Eq. 1)
where, \(\:Y\) represents the diffusion measure of FA, free water, or fwcFA, \(\:\beta\:,\:\)and \(\:\gamma\:\:\) stand for regression parameters, \(\:\alpha\:\) is the intercept, and \(\:\epsilon\:\:\)represents the random error. This analysis was repeated 756 times (378 diffusion measures \(\:\times\:\) 2 groups = 756).
Clinical correlation assessments. Nonparametric partial correlation analyses with 5000 permutations were conducted to examine the relationship between dMRI measures that significantly differentiated autistic adults and neurotypical controls and clinical measures of ASD (AQ, SRS-2, RBS-R, and ADOS-2) [49].
Correction for multiple comparisons. ANCOVAs and nonparametric partial correlations were corrected for multiple comparisons using the false discovery rate (FDR) [53]. For each statistical approach, FDR was applied separately within each combination of diffusion measure and white/gray matter tissue category (e.g., FA in white matter, free water in gray matter). The q threshold was set at 0.05 [54]. Statistical analyses were conducted using SPSS version 29 (IBM SPSS Statistics, Armonk, NY, USA) and R version 4.2.2 (https://www.R-project.org).